Girard Gibbs LLP is investigating claims on behalf of investors of
Acorda Therapeutics, Inc. (NASDAQ:ACOR) regarding possible violations of
federal securities laws following the FDA’s refusal to review the
company’s new drug application for Inbrija.
To speak privately with an attorney regarding this class action
lawsuit investigation, click
On August 29, 2017, Acorda announced that it had received a Refusal to
File letter from the FDA regarding the company’s New Drug Application
for Inbrija. Specifically, the FDA determined that the New Drug
Application was not complete enough to permit a substantive review. The
FDA cited two specific issues: 1) the date the manufacturing site would
be ready for inspection; and 2) a question regarding the submission of
the drug master production record. The FDA has also requested further
information at resubmission, which did not form the basis for the
Refusal to File.
Following this news, Acorda share price plummeted by more than 24% to
close at $19.45 on August 29, 2017.
If you purchased or acquired shares of Acorda Therapeutics and would
like to speak privately with a securities attorney to learn more about
the investigation and your legal rights, visit our website
or contact the securities team directly at (800) 254-9493.
Girard Gibbs LLP is one of the nation’s leading firms representing
individual and institutional investors in securities
litigation to correct abusive corporate governance practices,
breaches of fiduciary duty, and proxy violations. The firm has recovered
over a billion dollars for its clients against some of the world’s
largest corporations, and has earned Tier-1 rankings and been named in
Lawyers – Best Law Firms list for five consecutive years.
This press release may constitute Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.